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Background: Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating
the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to
malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to
these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluated EGFR
mutation profile as well as the presence of mutations in hotspots of KRAS and BRAF in ESCC patients.
Methods: We performed RT-qPCR, immunohistochemistry and Fluorescent in situ hybridization to determine EGFR
and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism
analysis.
Results: Our results showed an increased EGFR mRNA expression in tumors compared to surrounding tissue
(p <0.05), with 11% of the cases presenting at least a four-fold difference between tumor and paired adjacent
mucosa. EGFR protein overexpression was present only in 4% of the cases. The median expression of HER2 mRNA
was not different between tumors and adjacent mucosa. Still, 7% of the tumors presented at least a 25-fold higher
expression of this gene when compared to its paired counterpart. Immunohistochemical analysis revealed that 21%
of the tumors were positive for HER2 (scores 2+ and 3+), although only 3+ tumors presented amplification of this
gene. Mutation analysis for EGFR (exons 18-21), KRAS (codons 12 and 13) and BRAF (V600E) showed no mutations in
any of the hotspots of these genes in almost 100 patients analyzed. EGFR presented synonymous polymorphisms at
codon 836 (C>T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was
also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC
patients. The absence of mutations of EGFR, KRAS and BRAF as well as the overexpression of EGFR and HER2 in less
than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with
ESCC.
Conclusion: HER receptors target therapies may have the potential to be effective in only a minor fraction of
patients with ESCC.
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Esophageal cancer (EC) is among the ten most incident
tumors in the world, and esophageal squamous cell car-
cinoma (ESCC) is the most frequent type of EC. In
addition to its high incidence, ESCC ranks fifth in cancer
mortality in men and eighth in women. ESCC mortality
and incidence rates are similar, with the 5 year overall
survival rate being below 15% [1,2]. The poor prognosis
of ESCC patients results from late stage diagnosis and
the poor efficacy of treatment, with systemic chemother-
apy having mainly a palliative role [3]. Although a num-
ber of cytotoxic drugs have been used to treat ESCC
patients, overall survival rates have not improved [4].
Therefore, the development of new therapy modalities,
particularly targeted therapies based on the knowledge of
the biology and genetics of the disease may offer a poten-
tial for improving treatment response and life quality for
ESCC patients [5]. Drugs targeting the human epidermal
growth factor receptors (HER) may act in two manners: as
tyrosine kinase activity inhibitors (TKIs) or as receptor
blocking monoclonal antibodies (mAbs) [6]. A number of
these drugs, such as gefitinib used to treat non-small cell
lung cancer, cetuximab used to treat patients diagnosed
with advanced colorectal cancer, and particularly trastuzu-
mab used to treat breast cancer patients, have shown sub-
stantial improvement in tumor response when compared
with conventional chemotherapy [7-9].
Among HER family members, EGFR (HER1) and
HER2 are the most commonly altered receptors in
human malignancies [10]. These receptors are mainly
involved in cell proliferation and survival through activa-
tion of PI3K-Akt [11], STAT3 [12], and Ras-Raf-MAPK
signaling pathway, with the latter described as the main
pathway activated by EGFR [13]. The most common
EGFR alterations found in tumors are mRNA and pro-
tein overexpression, often associated with gene amplifi-
cation, followed by mutations in specific hotspots
located in the region that encodes the tyrosine-kinase
domain of the receptor [14]. The increased expression of
EGFR is mainly found in head and neck cancers, in
which 70-90% of the cases show this profile [15]. Com-
plementary, EGFR mutations were firstly reported in
lung cancer patients who had greater response to treat-
ment with EGFR tyrosine kinase inhibitors. These muta-
tions are generally found in the exons 18-21 of the gene
and are more prevalent in Asian non-smoker women
with lung adenocarcinoma [16]. The role of HER2 in
tumorigenesis is a consequence of abnormally increased
protein expression, as a result of gene amplification. This
phenomenon is observed in more than 25% of breast
cancer patients and more recently in about 15-25% of
gastric cancer patients [17,18].
In addition to the alterations in HER receptors, muta-
tions in genes involved in the signaling pathways activatedby these receptors are also correlated with the carcinogen-
esis process and failure of therapeutic response to HER
inhibitors [14]. For instance, colorectal cancer patients
who present mutations in KRAS or BRAF do not respond
to panitumumab, a monoclonal antibody against EGFR,
recently approved by FDA as a monotherapy against
metastatic colorectal carcinoma [19].
Since EGFR and HER2 alterations may predict a suc-
cessful response to HER target specific therapy, and
ESCC has a very poor prognosis with currently available
treatments, it is essential to analyze possible alterations
of these receptors in ESCC, to evaluate the potential of
use of anti-HER therapy to treat ESCC patients.
Methods
Samples
Two-hundred and forty one patients with a confirmed his-
tologically diagnosis of ESCC who had not undergone
chemo or radiotherapy were recruited between 1997 and
2010 from four hospitals in Brazil: Hospital Universitário
Pedro Ernesto (HUPE-UERJ, Rio de Janeiro), Instituto
Nacional do Câncer (INCA, Rio de Janeiro), Hospital de
Clínicas (HCPA-UFRGS, Porto Alegre), and Hospital de
Clínicas-Gastrocentro (HC-UNICAMP, Campinas). Tumor
and adjacent mucosa were obtained either as formalin
fixed paraffin embedded (FFPE), or fresh snap frozen tis-
sue. Patients’ information was collected either from their
medical records, or from a standardized questionnaire. In
addition to patients, 304 subjects without cancer were
included in the study (control group), from whom 5 mL of
peripheral blood were collected. The controls also
answered the standardized questionnaire and all patients
signed a consent form. The project was approved by the
Ethic Committees of all institutions involved.
DNA and RNA isolation
The DNA isolation from frozen samples was performed
according to Sambrook and colleagues [20], while DNA
isolation from FFPE samples was carried out using the
QIAamp DNA FFPE Tissue kit (QIAGENW, Germany).
DNA was also isolated from blood lymphocyte (control
group) using the proteinase K/sodium dodecyl sulfate
digestion as described by Miller and colleagues [21].
Finally, total RNA was extracted from tissues using the
TRIzolW (Invitrogen, USA) reagent following the proto-
col described by the manufacturer. All RNA samples
were quantified by spectrophotometry and their integrity
was evaluated by formaldehyde-agarose gel electrophor-
esis. The quality of the RNA samples was determined by
the ratio of the 28S, 18S and 5.8S ribosomal RNA bands.
PCR and direct sequencing
In order to assess the viability of DNA extracted from
FFPE samples, amplification of β-actin was performed.
Gonzaga et al. BMC Cancer 2012, 12:569 Page 3 of 10
http://www.biomedcentral.com/1471-2407/12/569Amplification of EGFR (exons 18- 21) [22], KRAS (exon 2),
BRAF (exon 15) and β-actin was done according to the fol-
lowing protocol: 1X PCR buffer (Invitrogen, USA), 3 mM
MgCl2 (Invitrogen, USA), 0.2 mM dNTPs, 0.5 U of GoTaq
Polymerase (Promega, USA), 3 pmol of each primer up to
25 μL. For amplification, the DNA was first denatured for
5 min at 94°C and followed by 40 PCR cycles consisting of
three steps: denaturation for 30 seconds at 92°C, annealing
for 1 minute at specific primer annealing temperature and
extension for 1 minute at 72°C. To assess β-actin amplifi-
cation we used 100 ng of genomic DNA, while for KRAS
and BRAF analysis we used 300 ng of DNA from FFPE and
100 ng of DNA from frozen samples. All oligonucleotides
used are summarized in Table 1. PCR products were then
purified with the PureLink™ Genomic DNA Purification kit
according to the manufacturer’s protocol (Invitrogen,
USA). Sequencing reactions contained 2 μL of purified
PCR product, 40 ng of primer (sense or anti sense) and
2 μL of the kit (ET Dye Terminator Cycle Sequencing Kit -
GEW Healthcare, UK) and were analyzed on a MegaBACE
1000 automatic sequencer (GE Healthcare, UK).
RT-qPCR
In order to synthetize cDNA, two to four micrograms of
total RNA were used in reverse transcription (RT)Table 1 Conditions of PCR reactions: oligonucleotide sequenc
reactions, and amplicon size
Genes Oligonucleotide sequences (5′-3′)
EGFR – exon 18 S F: CAAATGAGCTGGCAAGTGCCGTGTC
AS R: GAGTTTCCCAAACACTCAGTGAAAC
EGFR – exon 19 S F: GCAATATCAGCCTTAGGTGCGGCTC
AS R: CATAGAAAGTGAACATTTAGGATGTG
EGFR – exon 20 S F: CCATGAGTACGTATTTTGAAACTC
AS R: CATATCCCCATGGCAAACTCTTGC
EGFR – exon 21 S F: TAACGTTCGCCAGCCATAAGTCC
AS R: GCTGCGAGCTCACCCAGAATGTCTGG
β-actin S F: GATGAGATTGGCATGGCTTT
AS R: CACCTTCACCCGTTCCAGTTT
BRAF S F: CCTTTACTTACTACACCTCAGATA
AS R: AATCAGTGGAAAAATAGCCT
KRAS S F: TGATAGTGTATTAACCTTATGTGTGAC
AS R: TCTATTGTTGGATCATATTCGTC
GAPDH S F: CAACAGCCTCAAGATCATCAGCAA
AS R: AGTGATGGCATGGACTGTGGTCAT
EGFR S F: TAACAAGCTCACGCAGTTGG
AS R: GTTGAGGGCAATGAGGACAT
HER2 S F: CTCCTGTGTGGACCTGGATGAC
AS R: GCTGCCGTCGCTTGATGA
ª Annealing Temperature.
b Designed by authors.reactions as previously described [23]. Equal amounts of
RNA samples from the same patient (tumor and adja-
cent mucosa) were used in separate RT reactions.
For the individual evaluation of EGFR, HER2 and
GAPDH expression, one pair of primers spanning
intron-exon junctions were designed and are described
in Table 1. The PCR was performed in the thermocycler
Chromo 4 (MJ ResearchW). Each reaction consisted of
7.5 μL of Faster EvaGreen 2X Master MixW (Biotium,
CA, USA), 10 pmols of oligonucleotide, 2 μL of cDNA
(diluted 10X) and sterile deionized water to complete
the final volume of 15 μL. The amplification reaction
was performed as follows: five minutes of pre-
denaturation at 95°C, followed by 40 cycles of denatur-
ation for 15 seconds at 95°C and an annealing and ex-
tension step for 1 minute at 60°C. After the reaction,
EGFR and HER2 mRNA expression was normalized by
the expression of GAPDH. The mRNA relative quantita-
tion was done using the ΔCt method. The parameter Ct
(threshold) was defined as the number of cycles in which
the fluorescence exceeded the previously set threshold.
The difference (ΔCt) between the average (three experi-
ments) of the gene of interest (EGFR or HER2) and the
housekeeping gene (GAPDH) was calculated using the
software Microsoft Excel.es, annealing temperatures, number of cycles of the
ATa Cycles Amplicon size (bp) Reference
56°C 35 400 [22]
58°C 35 372 [22]
54°C 35 408 [22]
58°C 35 414 [22]
55°C 40 100 b
54°C 40 189 b
54°C 40 170 b
60°C 40 123 b
60°C 40 178 b
60°C 40 143 b
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The EGFR gene polymorphism was determined using the
PCR-RFLP method. New primers were designed to
proceed restriction endonuclease reaction (EGFR Sense:
50CATGAGTACGTATTTTGAAACTC30; and Anti-sense:
50CACACACCAGTTGAGCAGGTA30) and the PCR re-
action was performed as follows: 25 ng of genomic DNA,
1X PCR buffer (Invitrogen, USA), 3 mM MgCl2 (Invitro-
gen, USA), 0.2 mM dNTPs, 0.5 U of GoTaq Polymerase
(Promega, USA), 3 pmol of each primer up to 25 μL. For
amplification, the DNA was first denatured for 5 min at
94°C and followed by 35 cycles consisting of three steps:
denaturation for 30 seconds at 92°C, annealing for 1 mi-
nute at 58°C annealing temperature and extension for 1
minute at 72°C. Two microliters of the PCR product (410
bp) were incubated with 2.5 U of BsgI (New England
BiolabsW) for 18 hours at 37°C, and the resulting frag-
ments were visualized on a 2.5% agarose gel stained with
SYBRW Safe (InvitrogenW). The genotypes were classified
as wild type homozygous (95 and 201 bp), heterozygous
(95, 201 and 296 bp) and variant homozygous (296 pb).
Immunohistochemistry (IHC)
Immunohistochemistry was performed on paraffin sec-
tions of 69 ESCC cases. For antigen retrieval, sections
were incubated in a pressure cooker while submerged in
a citrate buffer solution, pH 6.0, for 3 min at 121°C. Sec-
tions were incubated with the primary antibody against
EGFR (Code 4267 - Cell SignalingW; diluted 1:300 in
diluent solution) [24] and HER2 (Code-A048529 1 -W
Dako; diluted 1:4000 in diluent solution) [25] overnight
at 4°C. Sections were then washed and covered with
biotinylated secondary antibody for 30 min at room
temperature followed by incubation in streptavidin–
peroxidase solution for 30 min. The detection system
was a Detection Novolink Polymer Systems (Leica Bio-
systemsW), using diaminobenzidine (DAB) as substrate.
Sections were counterstained with Harris’ hematoxylin.
FFPE lung and breast cancer tissue served as positive
controls of EGFR and HER2, respectively. For a negative
control, the primary antibody was replaced with the
antibody diluent solution.
The staining score evaluation was performed by two in-
dependent pathologists. For HER2 scores, we used the Her-
cepTest™ (DakoW) indicated to assess HER2 staining in
breast cancer, with a similar cut-point of 10% of positive
tumor cells used to consider positive staining for HER2. To
evaluate EGFR staining score, we used the method
described by Pirker and colleagues [26] as follows:
1xð Þ þ 2yð Þ þ 3zð Þ ≥ 200 Positiveð Þ
1xð Þ þ 2yð Þ þ 3zð Þ < 200 Negativeð ÞWhere x is the percentage of tumor cells with 1+ score
(weak staining), y is the percentage of tumor cells with
2+ score (moderate staining) and z is the percentage of
tumor cells with 3+ score (strong staining).
Fluorescent in situ hybridization (FISH)
The cases classified as HER2 positive in immunohisto-
chemistry analysis (2+ and 3+ scores) were subjected to
gene amplification analysis by FISH using the HER2
FISH pharmDx™ kit (DakoW). Tissue sections (3 μm)
were incubated for 30 minutes in a solution of 0.2 N
HCl at room temperature. Then, they were immersed in
citrate buffer pH 6.0 for 30 minutes at 98°C and fol-
lowed the manufacturer’s protocol. To evaluate HER2
amplification we counted the red (HER2) and green sig-
nals (Centromere 17 - CEN17) in twenty nuclei of each
tumor. If HER2/CEN17 ≤ 1.8, the sample is classified as
non-amplified; 1.8 <HER2/CEN17 ≤ 2.2, as indetermin-
ate status; and if HER2/CEN17> 2.2, the sample was
classified as amplified. The adjacent normal tissues were
used as internal controls of the reaction.
Statistical analysis
Allele frequencies of EGFR were calculated and tested
for Hardy-Weinberg equilibrium within cases and con-
trols. To determine if there were differences in mRNA
expression of EGFR and HER2 in tumor when compared
to paired adjacent mucosa we used Wilcoxon signed-
rank test. Outliers were assessed by Grubbs test. All stat-
istical analysis was performed with GraphPad Prism 5
(GraphPad Software, USA).
The total number of patients (241) was divided into
smaller groups according to the analysis performed, due
to heterogeneity in sample quality. The RT-qPCR and se-
quencing analyses had to additionally rely on a number of
frozen tumors to reach acceptable statistical power [27].
Results
Patients and tumors characteristics
The characteristics of the patients are summarized in
Table 2. The median age of patients was 58 years, ran-
ging from 34 to 88 years, with most of the patients being
male (64%), alcohol drinkers (58%) and smokers (65%),
with a median tobacco consumption above 30 packs/
year. The tumors were located most often in the middle
third of the esophagus, with a higher prevalence of T3
and T4 classification.
EGFR alterations in ESCC
EGFR, KRAS and BRAF mutations
Initially we analyzed potential alterations in exons 18 to
21 of EGFR, and found no mutations among the 135
samples studied. However, a synonymous polymorphism
in exon 20 (Q787Q - G2607A; ID: rs1050171) was
Table 2 Characteristics of the individuals included in this
study (% of the total of patients)
Controls Patients
Samples, n(%)
FFPE samples - 98 (41)
Frozen Samples - 143 (59)
Blood samples 304 (100) -
Total 304 (100) 241 (100)
Gender, n(%)
Male 140 (46) 154 (64)
Female 163 (54) 50 (21)
Median Age (years) 54 58
Range 19-89 34-88
Alcohol Consumption, n(%)
Never drink 214 (70) 30 (12)
Current Drinker 83 (27) 139 (58)
Tobacco Consumption, n(%)
Never smoke 133 (44) 18 (7)
Current Smoker 164 (54) 157 (65)
Packs/Year Index, n(%)
≤ 30 92 (69) 63 (26)
> 30 24 (18) 88 (37)
T (TNM), n(%)
Ti - 1 (0,4)
T1 - 10 (4)
T2 - 16 (7)
T3 - 61 (25)
T4 - 34 (14)
*Number of patients may vary due to missing data.
Table 3 Genotype frequencies of EGFR polymorphism
G2607A in ESCC patients and control group
G2361A EGFR polymorphism Patients Controls
Wild-type homozygous (GG) 28 (21%) 80 (26%)
Heterozygous (GA) 72 (53%) 138 (45%)
Variant homozygous (AA) 35 (26%) 86 (28%)
Total 135 (100%) 304 (100%)
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tributed as follows: 28 (21%) wild-type homozygous
(GG), 72 (53%) heterozygous (AG) and 35 (26%) variant
homozygous (AA). The genotypic frequencies were in
Hardy-Weinberg equilibrium (p> 0.05). In addition, an-
other synonymous polymorphism was found in exon 21
(R836R - C2754T; ID: rs17290559) in three patients
(2%), all heterozygous.
Due to the high frequency of the G2607A polymorph-
ism in ESCC patients, we decided to investigate whether
this variant confers a risk for esophageal cancer develop-
ment in a case-control study. With this purpose, the
presence of this polymorphism was assessed by PCR-
RFLP in a group of 304 individuals without cancer. Out
of the 304 subjects, 80 (26%) were wild-type, 138 (45%)
were heterozygous and 86 (28%) were variant homozy-
gous. The genotypic frequencies were in Hardy-
Weinberg equilibrium (p> 0.05) and there was no associ-
ation between the presence of the polymorphism and
ESCC (p> 0.05) (Table 3).A total of 91 samples were investigated for the pres-
ence of potential mutations in KRAS (codons 12 and 13)
and BRAF (V600E), with none of them being positive.
EGFR expression
The mRNA expression profile of EGFR was analyzed in
37 matched samples (tumor and adjacent tissue) with a
higher median EGFR expression in tumors in compari-
son with surrounding mucosa (p <0.05) (Figure 1A). The
paired sample analysis revealed that 16 (43%) tumors
showed at least a 1.5-fold higher expression of EGFR
when compared with the adjacent mucosa. Among
these, 25% (11% of all samples) showed an overexpres-
sion above 4-fold (ranging from 4.2- to 9.7-fold), and
these were confirmed as outliers (p <0.05).
Next, we evaluated EGFR protein expression by immu-
nohistochemistry in 69 ESCC samples. Sixty-six tumors
(96%) were classified as negative for EGFR staining,
while only three (4%) showed EGFR positive staining in
the tumor area (Figure 2). The staining was localized
mainly in the cell membrane with a weaker staining in
cytoplasm. All of the three positive cases presented
EGFR staining in the entire tumor. However, one case
showed a heterogeneous staining, while the other two
cases presented a homogeneous EGFR staining. The ad-
jacent normal tissue showed a weak homogeneous stain-
ing predominantly localized in the basal layer.
The tumors that presented the highest EGFR expres-
sion were not correlated with any of the clinicopatholo-
gical parameters analyzed in this study.
HER2 alterations in ESCC
HER2 expression and amplification
The evaluation of HER2 mRNA levels included 30
matched samples (tumor and adjacent tissue). There was
no difference in the median expression of HER2 expres-
sion in tumors in comparison with the surrounding tis-
sue (p> 0.05) (Figure 1B). However, two samples (7%)
showed HER2 overexpression higher than 25-fold (25.2-
and 37.8-fold) in tumor tissue when compared to its
matched adjacent mucosa, which were confirmed as
outliers (p <0.05).
HER2 protein expression was also analyzed by immu-
nohistochemistry in 68 ESCC samples. A total of 39
tumors (57%) were negative for HER2 staining, 14 (21%)
Figure 1 Analysis of mRNA expression of EGFR and HER2 in ESCC patients: (A) Comparison of EGFR mRNA expression between tumor
and normal adjacent mucosa of 37 ESCC patients. (B) Comparison of HER2 mRNA expression between tumor and normal adjacent mucosa of
30 ESCC patients.
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only 3 (4%) were scored 3+. Thus, 53 ESCC patients
(78%) were negative for HER2 expression (negative and
1+ scores) and 15 cases (22%) were initially considered
positive (2+ and 3+ scores) (Figure 3). A similar expres-
sion profile to that seen for EGFR was observed with
HER2 positive staining. The adjacent normal tissue also
presented a weak homogeneous staining in the basal
layer.
Among the 15 cases (22%) initially classified as HER2
positive by IHC, we were able to analyze gene amplifica-
tion by FISH on 11 (nine 2+ and two 3+) due to low ma-
terial availability in 4 samples. Amplification of HER2
was confirmed in the two cases classified as score 3+ by
IHC. One sample presented a heterogeneous labeling
along the tumor field with some areas presenting gene
amplification and areas with normal signal (non-Figure 2 Expression of EGFR in ESCC by immunohistochemistry. (A) R
its corresponding negative control. (C) Representative figure of a EGFR negamplified). The other sample exhibited a homogeneous
signal, in which the entire tumor extension showed
HER2 amplification (Figure 4A). Score 2+ samples
showed no gene amplification (Figure 4B).
The tumors that presented the highest HER2 expres-
sion were not correlated with any of the clinicopatholo-
gical parameters analyzed in this study.Discussion
The present study revealed that ESCC of Brazilian patients,
who largelly present typical western characteristics, do not
present mutations in hot spots of EGFR (exons 18-21), K-
RAS (codons 12 and 13) and BRAF (V600E), and only a
minor proportion (4%) present overexpression of EGFR or
HER2. These results indicate that common alterations in
EGFR and HER2 receptors and in the Ras-Raf-MAPKepresentative figure of a EGFR positive staining case in ESCC, and (B)
ative case in ESCC, and (D) its corresponding negative control.
Figure 3 Expression of HER2 in ESCC by immunohistochemistry. (A) Representative image of HER2 negative score in ESCC, and (B) its
corresponding negative control. (C) Representative image of HER 2 Score 1+ in ESCC, and (D) its corresponding negative control. (E)
Representative image of HER 2 Score 2+ in ESCC, and (F) its corresponding negative control. (G) Representative image of HER 2 Score 3+ in ESCC,
and (H) its corresponding negative control.
Figure 4 HER2 gene amplification by FISH. (A) Representative image of a positive case for HER2 amplification in ESCC. (B) Representative
image of a negative case for HER2 amplification in ESCC.
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tumors, are rare in ESCC from Brazilian patients.
EGFR alterations in cancer can be divided mostly in
two categories: mutations in exons 18-21, which encode
the tyrosine kinase portion of the receptor, and gene and
protein overexpression. EGFR mutations are mostly
observed in lung tumors, and curiously they are more
prevalent in Asian women diagnosed with adenocarcin-
oma who never smoked [16]. The most frequent EGFR
mutations are deletions in exon 19 and a point mutation
in codon 858 of exon 21, known as L858R (T2573G; ID:
rs121434568) [16]. Patients who carry these mutations
in EGFR tend to have a better response to gefitinib, an
EGFR-TKI, whereas patients with the wild-type genotype
show a better response to conventional chemotherapy
[7]. This could be explained by the fact that the mutated
receptor possess a greater affinity to the drug in com-
parison with ATP, and therefore cannot initiate the
phosphorylation cascade downstream through the sig-
naling pathways that lead to proliferation and cell sur-
vival. However, about 50% of lung cancer patients
treated with EGFR-TKI acquire a secondary mutation
that confers drug resistance, the T790M (C2369G; ID:
rs121434569), located in exon 21 of the gene, which
reduces the affinity of the ATP-binding site for the drug
[15]. In addition to lung cancer, other tumors present
low frequencies of EGFR mutations, like head and neck
cancers, with no more than 7% of the patients carrying
these alterations [28]. Our results showed no mutations
in exons 18 to 21 of EGFR in 135 ESCC patients. So far,
few studies were published that analyzed mutations in
EGFR in ESCCs [29-31]. Among these, only one report
found mutations in this gene (in 14% of tumors). How-
ever this study was carried out with Chinese patients,
who usually present a different set of etiological factors
when compared to western patients. Furthermore, the
authors used the Scorpions Amplification Refractory
Mutation System, a non-conventional methodology for
the identification of mutations [31]. Our study also iden-
tified two synonymous polymorphisms: one at codon
787, in exon 20, with a G>A transition, found in more
than 79% of the patients, without any significant differ-
ence to controls, and another at codon 836, in exon 21,
with a C>T transition in only 2% of the patients.
It is estimated that 33-50% of epidermal tumors present
overexpression of EGFR [14], being observed in more than
90% of head and neck tumors [15]. In addition to protein
overexpression, around 10-17% of the head and neck tumors
present EGFR gene amplification, as shown by FISH analysis
[28]. In 2006, the FDA approved the use of cetuximab, a
chimeric anti-EGFR mAb, for the treatment of patients with
head and neck tumors presenting overexpression of this pro-
tein. The use of cetuximab was approved for the first time in
2004 for the treatment of colorectal cancer, which has highresponse rates to this drug (about 47% of the patients) [8], al-
though there is no concordance in the literature about the
role of EGFR expression as a biomarker for response to this
targeted therapy [32-34]. More recently, Panitumumab, a
humanized anti-EGFR mAb, was also approved to colorectal
cancer treatment, with good results in therapeutic efficacy
[35]. However, several reports showed that mutations in
genes involved in the Ras-Raf-MAPK pathway, like KRAS
and BRAF, are important biomarkers for colorectal tumor
patient response to anti-EGFR mAbs. These mutations turn
these proteins constitutively activated, resulting in a
receptor-independent activation of the pathway, what culmi-
nates in the resistance to treatment with anti-EGFR mAbs
[36]. The most frequent mutations observed in colorectal
cancer patients are found at codons 12 and 13 of KRAS, in
approximately 35% of the patients, and the V600E mutation
of BRAF, found in about 15% of the cases [19,34]. Head and
neck tumors present mutations in KRAS and BRAF, but in
very low frequencies, with 6% of the patients carrying a mu-
tation in KRAS and 3% in BRAF [37]. In our study, 11% of
ESCC tumors presented elevated EGFR mRNA levels in
comparison with the normal adjacent mucosa, while only 4%
showed protein overexpression. Previous studies analyzing
EGFR expression in ESCC showed protein overexpression in
more than 40% of ESCC patients, with 15% of cases present-
ing gene amplification [30,38]. This difference may be
explained by the different methodologies used to score EGFR
staining by IHC. In this study we evaluated EGFR staining
score by the method reported by Pierker et al. [26], where a
sample with weak staining is not considered positive for
EGFR expression. In the other studies [30,38], the scoring
method adopted was less stringent. Nevertheless, differences
among the populations that took part in our and in the other
studies may also explain this difference.
We found no alterations in hotspots of KRAS and
BRAF in ESCC patients. This data is in accordance with
the study developed by Hollstein and colleagues, who
previously described the absence of mutations in KRAS
in ESCC of patients from Normandy (France) and
Uruguay [39], while no study had investigated BRAF
mutations in ESCC so far. Therefore, our results both
on EGFR hot-spot mutations and expression suggest that
the EGFR-Ras-Raf-MAPK pathway is not associated with
esophageal carcinogenesis.
HER2 overexpression, as a consequence of gene amplifi-
cation, was initially seen to be present in around 25% of
breast cancer patients, and more recently in a similar per-
centage of stomach and esophagogastric junction tumors
[40]. These findings became even more relevant with the
possibility to use a HER2-specific antibody, trastuzumab, to
treat these patients [41]. Breast cancer patients, who
present HER2 overexpression and gene amplification, and
are treated with trastuzumab present a response rate of
62%, that is substantially higher when compared with 32%
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demonstrated that 7% of the ESCC tumors show high
HER2 mRNA levels compared to the adjacent tissue,
whereas 22% showed protein overexpression. Gene amplifi-
cation was confirmed in 4% of the cases by FISH, a fre-
quency comparable to that of increased mRNA levels.
Some studies focused on ESCC already described a 3-fold
higher frequency of patients with score 2+ for HER2 in
comparison with those with score 3+. Besides, those reports
also showed that every sample classified as score 3+ pre-
sented HER2 amplification, similarly to our findings [42,43].
Interestingly, the frequency of cases with high HER2
mRNA expression and gene amplification is much lower
than those with protein overexpression, which could be
explained by HER2 biology. It has been described previ-
ously that dimmers containing HER2 generally tend to re-
main longer in the plasma membrane and are not targeted
for proteolytic degradation, returning to the membrane in a
process called recycling [44]. This phenomenon could ex-
plain why cases scored as 2+, considered as protein overex-
pression, do not show gene amplification.
A limitation of this study was that although we initially
had 241 tumor samples, these were divided into smaller
groups according to the different assays performed, due to
the heterogeneity in sample amount and quality. Although
this solution may have generated results with a limited
number of samples in some of the analyses, a sufficient
statistical power was reached in all cases [27]. Therefore,
we may suggest that HER-activated pathway does not play
a predominant role in esophageal carcinogenesis in the vast
majority of cases. Furthermore, the absence of any EGFR,
KRAS and BRAF mutations as well as a frequency of HER
overexpression of less than 10% may also suggest that these
modifications could be lethal to esophageal cells during
transformation. In accordance with this speculation, Kim
and colleges showed that EGFR-induced human esopha-
geal tumor presents a strong TUNEL staining [45], what
suggests that EGFR overexpression tends to induce apop-
tosis pathways in esophageal cells. However, other in vitro
studies are still necessary to confirm this hypothesis.
Conclusion
This study shows that most ESCC patients do not have
the molecular profile for anti-HER targeted therapy.
Thus, other markers should be investigated in the pur-
suit of new treatments that could increase survival and
life quality of these patients.
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